Last reviewed · How we verify
aspirin continuation
Aspirin continuation works by inhibiting the enzyme cyclooxygenase, which is involved in the production of prostaglandins and thromboxanes, leading to a decrease in platelet aggregation and blood clot formation.
Aspirin continuation works by inhibiting the enzyme cyclooxygenase, which is involved in the production of prostaglandins and thromboxanes, leading to a decrease in platelet aggregation and blood clot formation. Used for Prevention of cardiovascular events in patients with a history of myocardial infarction or stroke.
At a glance
| Generic name | aspirin continuation |
|---|---|
| Also known as | Low-dose aspirin (< 100mg/day), initiation of aspirin in early pregnancy |
| Sponsor | Seoul National University Hospital |
| Drug class | NSAID |
| Target | COX |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aspirin continuation is a long-term treatment that continues the antiplatelet effects of aspirin, which is a nonsteroidal anti-inflammatory drug (NSAID). By inhibiting cyclooxygenase, aspirin continuation reduces the production of thromboxane A2, a potent stimulator of platelet aggregation, thereby decreasing the risk of blood clots and cardiovascular events.
Approved indications
- Prevention of cardiovascular events in patients with a history of myocardial infarction or stroke
Common side effects
- Gastrointestinal bleeding
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy (PHASE3)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
- Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma (NA)
- Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia (PHASE3)
- Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin continuation CI brief — competitive landscape report
- aspirin continuation updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI